Alexis Rovner

Alexis Rovner, also known as Lexi Rovner, is the Co-founder and CEO of 64x Bio, a biotechnology company based in San Francisco that specializes in cell line engineering for gene therapy manufacturing. She has been in this role since June 2018, leading efforts to develop high-throughput genome engineering technologies aimed at improving the efficiency and accessibility of cell and gene therapies.12

Educational Background

Rovner holds a Ph.D. in Molecular, Cellular, and Developmental Biology from Yale University. Her academic journey included significant postdoctoral research at the Wyss Institute for Biologically Inspired Engineering and Harvard Medical School, where she worked under the mentorship of renowned scientist George Church.13

Career Highlights

• 64x Bio: Founded in 2018, the company focuses on creating optimized mammalian cell lines for viral vector production, addressing critical bottlenecks in the biotechnology industry. Under her leadership, 64x Bio raised $55 million in Series A funding to advance its innovative platform technologies.246
• Research Experience: Prior to founding 64x Bio, Rovner was a postdoctoral fellow where she co-developed proprietary technologies that are now integral to her company's operations.35

Vision and Impact

Rovner's work at 64x Bio aims to revolutionize the manufacturing processes for gene therapies, making them more efficient and cost-effective. She emphasizes the importance of understanding market needs and developing solutions that address significant challenges within the biotech sector.34

In summary, Alexis Rovner is a prominent figure in the biotechnology field, leveraging her extensive scientific background to lead innovations that could transform how cell and gene therapies are produced.